Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients With Advanced Solid Tumors, Phase I Studies With Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)

NCT04514497 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04514497
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04514497 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients With Advanced Solid Tumors, Phase I Studies With Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 20, 2021
Completion date
March 4, 2027
Enrollment
29 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic lung small cell carcinoma, metastatic malignant solid neoplasm, metastatic neuroendocrine carcinoma, metastatic pancreatic adenocarcinoma, stage iii lung cancer ajcc v8, stage iii pancreatic cancer ajcc v8, stage iv lung cancer ajcc v8, stage iv pancreatic cancer ajcc v8, unresectable lung small cell carcinoma, unresectable malignant solid neoplasm, unresectable neuroendocrine carcinoma, unresectable pancreatic adenocarcinoma